Hua Medicine (Shanghai) Ltd. (OTCMKTS:HUMDF – Get Free Report) was the target of a large decline in short interest in June. As of June 30th, there was short interest totaling 13,945 shares, a decline of 40.1% from the June 15th total of 23,273 shares. Based on an average trading volume of 0 shares, the days-to-cover ratio is presently ∞ days.
Hua Medicine (Shanghai) Price Performance
OTCMKTS HUMDF remained flat at C$0.34 on Thursday. The business has a 50 day simple moving average of C$0.39 and a 200 day simple moving average of C$0.41. Hua Medicine has a twelve month low of C$0.34 and a twelve month high of C$0.50.
About Hua Medicine (Shanghai)
Hua Medicine (Shanghai) is a clinical-stage biopharmaceutical company focused on the research, development and commercialization of innovative treatments for Type 2 diabetes and related metabolic disorders. The company’s pipeline comprises both oral and injectable candidates that leverage novel biological targets and proprietary chemistry to improve glycemic control, minimize side effects and enhance patient adherence.
Founded and headquartered in Shanghai, Hua Medicine has established research hubs and strategic partnerships across Asia and Europe.
Featured Stories
- Five stocks we like better than Hua Medicine (Shanghai)
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
- Why Microsoft Is Playing a Different AI Game Than Big Tech—and Cash Flow Is the Test
- Trump Accounts: Comparing the 5 Selected Low-Cost Index ETFs
- Toast’s Comeback Story Is Getting Harder for Wall Street to Ignore
Receive News & Ratings for Hua Medicine (Shanghai) Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hua Medicine (Shanghai) and related companies with MarketBeat.com's FREE daily email newsletter.
